What’s New in Retinoblastoma Research?

Over the past few decades, research into retinoblastoma has led to many advances in treatment, which in turn has led to much higher cure rates and fewer side effects. Still, not all children are cured, and even those who are cured might still have long-term side effects from treatment, so more research is needed.

Research on retinoblastoma is being done at many medical centers, university hospitals, and other institutions around the world.

Genetics, genetic testing, and gene therapy

The defective gene responsible for nearly all retinoblastomas (the RB1 gene) was identified in 1986. This discovery, along with technical advances in finding DNA changes, has made genetic testing for heritable (hereditary) retinoblastoma possible.

A great deal of research has gone into figuring out how certain DNA changes in retinal cells cause them to become cancerous. Scientists understand these changes better for retinoblastoma than for most other cancer types. Although probably still years away, researchers hope that this understanding will one day lead to gene therapies, very specific treatments that can repair or counteract these DNA changes.

For example, researchers have found that an oncogene known as SYK is overactive in retinoblastoma cells. Drugs that target the protein this gene makes are now being developed. Another gene called MDM4 also seems to be involved in the development of retinoblastoma, and drugs aimed at blocking its effects are being studied.

Researchers have also found that a very small portion of retinoblastomas don’t seem to have changes in the RB1 gene, but instead have too many copies of another gene called MYCN. These cancers seem to be different in some important ways from those with RB1 gene changes.


Research is building on the progress made in treating retinoblastoma over the past few decades.

Radiation therapy

External radiation therapy can be used to treat retinoblastoma, but it can cause side effects because the radiation often reaches nearby tissues as well. This is especially important in children with hereditary retinoblastoma, whose cells are more likely to be damaged by radiation.

Newer forms of radiation therapy such as intensity modulated radiation therapy (IMRT) and proton beam therapy can better target the tumor and spare nearby normal tissues. These techniques, which are described in Radiation Therapy for Retinoblastoma, may help doctors limit the side effects from radiation therapy.

Focal treatments

Doctors continue to improve the techniques used for cryotherapy, laser therapy (photocoagulation and thermotherapy), and other focal treatments. The goal is to kill tumor cells more precisely while sparing other parts of the eye.


Chemotherapy (chemo) has played a larger role in treating many retinoblastomas in recent years.

Systemic chemo: Chemo given into a vein (IV) is now commonly used to shrink tumors before local treatments such as cryotherapy or laser therapy. Chemo is also given to some children after the removal of the eye (known as adjuvant chemotherapy) to help prevent the recurrence of retinoblastoma outside the eye. Doctors are also studying the use of different chemo drugs, as well as new ways of combining currently used drugs, to try to improve how well chemo works.

Localized chemo: Doctors continue to improve upon newer ways of getting chemo into the eye, such as intra-arterial chemo and intravitreal chemo. These approaches let doctors get higher doses of chemo to the tumors while reducing many of the typical chemo side effects, and are quickly becoming part of the standard treatment for many retinoblastomas. These techniques are described in Chemotherapy for Retinoblastoma.

High-dose chemotherapy and stem cell transplant: A stem cell transplant (SCT) lets doctors give higher doses of chemo than could safely be given otherwise. (In the past, this type of treatment was commonly referred to as a bone marrow transplant.) Doctors are studying the use of this type of treatment in children with retinoblastoma that has spread outside the eye and who are unlikely to be cured with other treatments.

Chemo drugs can affect quickly dividing cells like those in the bone marrow, which is where new blood cells are made. Even though higher doses of these drugs might be more effective in treating tumors, they can’t be given because they would cause severe damage to bone marrow cells, leading to life-threatening shortages of blood cells.

To try to get around this problem, the doctor may treat the child with high-dose chemo (sometimes along with radiation therapy) and then use a stem cell transplant to “rescue” the bone marrow.

To learn more about stem cell transplants, including how they are done, see Stem Cell Transplant for Cancer.

Oncolytic virus therapy

Researchers are also trying to find ways to take advantage of the gene changes in retinoblastoma cells to treat these tumors. One example is VCN-01, a virus that’s been modified in the lab to infect and destroy cells that don’t have working copies of the RB1 gene (which includes the vast majority of retinoblastomas). This treatment is now being studied in the earliest phases of clinical trials.  

The American Cancer Society medical and editorial content team

Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as journalists, editors, and translators with extensive experience in medical writing.

Hurwitz RL, Shields CL, Shields JA, et al. Chapter 27: Retinoblastoma. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. 7th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2016.

Kaufman PL, Kim J, Berry JL. Retinoblastoma: Treatment and outcome. UpToDate. Accessed www.uptodate.com/contents/retinoblastoma-treatment-and-outcome on September 25, 2018.

Rodriguez-Galindo C, Orbach DB, VanderVeen D. Retinoblastoma. Pediatr Clin North Am. 2015;62(1):201-223.

Rushlow DE, Mol BM, Kennett JY, et al. Characterisation of retinoblastomas without RB1 mutations: Genomic, gene expression, and clinical studies. Lancet Oncol. 2013;14:327–334.

Zhang J, Benavente CA, McEvoy J, et al. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature. 2012;481:329–334.

Last Medical Review: December 3, 2018 Last Revised: December 3, 2018

American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.